2025-02-04 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Review

**0. Executive Summary:**

Intuitive Surgical Inc. (ISRG) is a leading medical device company focused on robotic-assisted surgery.  This report analyzes ISRG's performance compared to the S&P 500 (VOO), considering financial data, technical indicators, and recent earnings.

**1. Performance Comparison & Alpha/Beta Analysis:**

ISRG has significantly outperformed the S&P 500. The cumulative return of ISRG is 317.08%, while the S&P 500's is 119.91%.  This represents a difference of 197.2%, placing it at the 88.6th percentile of the historical range (max: 223.6, min: -7.9).

The provided alpha/beta analysis shows high CAGR (Compound Annual Growth Rate) values, indicating strong historical performance.  However, the significant MDD (Maximum Drawdown) values in some periods highlight the inherent risk associated with ISRG's volatility.  Alpha values fluctuate, suggesting periods of outperformance and underperformance relative to the market, while the beta consistently exceeds 1, indicating higher than average market volatility.  Market capitalization (Cap) shows consistent growth over the analyzed periods.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 77.0% | 7.3% | 49.0% | -0.0 | 44.0 |
| 2016-2018  | 89.0% | 8.9% | 71.0% | 0.0 | 57.7 |
| 2017-2019  | 93.0% | 9.8% | 63.0% | 0.5 | 71.2 |
| 2018-2020  | 71.0% | 9.8% | 43.0% | 0.2 | 98.6 |
| 2019-2021  | 113.0% | 9.8% | 42.0% | 0.2 | 129.9 |
| 2020-2022  | 21.0% | 20.6% | 12.0% | 0.2 | 95.9 |
| 2021-2023  | 19.0% | 20.6% | -4.0% | 1.0 | 121.9 |
| 2022-2024  | 128.0% | 20.4% | 95.0% | 1.0 | 188.7 |
| 2023-2025  | 211.0% | 9.9% | 150.0% | 0.8 | 206.7 |


**2. Recent Price Movement:**

* **Closing Price:** $571.88
* **Last Market Price:** $579.55 (1.34% increase from previous close)
* **5-day Moving Average:** $574.48
* **20-day Moving Average:** $567.01
* **60-day Moving Average:** $546.17

The price is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a short-term uptrend.  The recent price increase is notable.


**3. Technical Indicators & Expected Return:**

* **RSI:** 59.04 (Slightly above neutral; not overbought)
* **PPO:** -0.26 (Slightly negative; suggesting bearish momentum)
* **20-day Relative Divergence Change:** -2.8% (Short-term downward trend)
* **Expected Return (Long-term):** 22.4% (Significant outperformance relative to S&P 500 over 2+ years)


The recent price increase (1.34%) reflects a potential short-term bullish reversal, contradicting the slightly negative PPO and downward relative divergence. This warrants closer monitoring. The long-term expected return is very positive.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-10-18 | $1.59 | $2.04B       |
| 2024-07-19 | $1.48 | $2.01B       |
| 2024-04-19 | $1.54 | $1.89B       |
| 2023-10-20 | $1.18 | $1.74B       |
| 2024-10-18 | $1.18 | $1.74B       | *(Duplicate entry - assumed error)*

Revenue shows a generally upward trend, with some minor fluctuations. EPS is also generally increasing, although there is variation between quarters.  The duplicate entry needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B  | 68.04%        |
| 2024-09-30 | $2.04B  | 67.41%        |
| 2024-06-30 | $2.01B  | 68.30%        |
| 2024-03-31 | $1.89B  | 65.87%        |
| 2023-12-31 | $1.93B  | 66.24%        |

Revenue is growing steadily. Profit margins are consistently high and relatively stable, suggesting strong profitability.

**Capital and Profitability:**

| Quarter | Equity   | ROE     |
|---------|----------|---------|
| 2024-12-31 | $16.43B | 4.17%   |
| 2024-09-30 | $15.58B | 3.63%   |
| 2024-06-30 | $14.71B | 3.58%   |
| 2024-03-31 | $13.96B | 3.90%   |
| 2023-12-31 | $13.31B | 4.56%   |

Equity is growing, indicating financial strength. ROE (Return on Equity) fluctuates but remains positive, showcasing consistent profitability relative to shareholder equity.


**6. Overall Analysis:**

ISRG demonstrates a strong track record of growth and profitability, significantly outperforming the S&P 500 over the long term. While the stock exhibits volatility (high Beta and MDD), the consistent revenue growth, high profit margins, and strong long-term expected return suggest continued potential. However, recent technical indicators show some mixed signals (slightly negative PPO and short-term downward relative divergence).  Investors should carefully consider the historical volatility and current mixed signals before making investment decisions.  Further investigation into the duplicate earnings data entry is needed for a more complete analysis.  The long-term outlook for ISRG remains positive, particularly given the expected return analysis.
